SRSF9 Antibody

Code CSB-PA00214A0Rb
Size US$166
Order now
Image
  • Western blot
    All lanes: SRSF9 antibody at 2µg/ml + Mouse kidney tissue
    Secondary
    Goat polyclonal to rabbit IgG at 1/10000 dilution
    Predicted band size: 26 kDa
    Observed band size: 26 kDa
The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) SRSF9 Polyclonal antibody
Uniprot No.
Target Names
SRSF9
Alternative Names
arginine/serine-rich 9 antibody; Pre mRNA splicing factor SRp30C antibody; Pre-mRNA-splicing factor SRp30C antibody; Serine/arginine-rich splicing factor 9 antibody; SFRS 9 antibody; Splicing factor antibody; Splicing factor arginine/serine rich 9 antibody; splicing factor, arginine/serine-rich 9 antibody; splicing factor, arginine/serine-rich, 30-KD, C antibody; SR splicing factor 9 antibody; SRP30C antibody; SRSF9 antibody; SRSF9_HUMAN antibody
Raised in
Rabbit
Species Reactivity
Human, Mouse
Immunogen
Recombinant Human Serine/arginine-rich splicing factor 9 protein (1-221AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The SRSF9 Antibody (Product code: CSB-PA00214A0Rb) is Non-conjugated. For SRSF9 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA00214B0Rb SRSF9 Antibody, HRP conjugated ELISA
FITC CSB-PA00214C0Rb SRSF9 Antibody, FITC conjugated
Biotin CSB-PA00214D0Rb SRSF9 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.1mol/L NaCl, 15mmol/L NaN3, PH7.2
Form
Liquid
Tested Applications
ELISA, WB
Recommended Dilution
Application Recommended Dilution
WB 1:1000-1:5000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Plays a role in constitutive splicing and can modulate the selection of alternative splice sites. Represses the splicing of MAPT/Tau exon 10.
Gene References into Functions
  1. Dehydroepiandrosterone (DHEA) and cortisol modulate SRSF9 and SRSF3 in a different way and data suggest that the anti-glucocorticoid effect of DHEA, among other mechanisms, is also exerted by modulating the expression of proteins involved in the splicing of the GR pre-mRNA. PMID: 28373129
  2. Report no correlation between expression of glucocorticoid receptor isoforms and SRp30c. PMID: 25665148
  3. Overexpression of SRSF9 and SRSF1 promote beta-catenin accumulation via the recruitment of beta-catenin mRNA and by enhancing its translation in an mTOR-dependent manner. PMID: 23592547
  4. Relative levels of SRp20, SRp30c, and SRp40 in TM cells control differential expression of the two alternatively spliced isoforms of the GR and thereby regulate GC responsiveness. PMID: 22205602
  5. these data indicated that tumor suppressive miR-1 induces apoptosis through direct inhibition of SRSF9 in bladder cancer. PMID: 22178073
  6. These results suggest that SRp30c can activate human papillomavirus type 16 L1 mRNA expression via a bimodal mechanism: directly by stimulating splicing to late splice sites and indirectly by inhibiting competing early splice sites. PMID: 21697349
  7. SRp30c can function as a repressor of 3' splice site utilization and suggest that the SRp30c-CE9 interaction may contribute to the control of hnRNP A1 alternative splicing. PMID: 12024014
  8. SRp30c protein is an interacting protein of YB-1 PMID: 12604611
  9. Serine-arginine-rich protein p30 directs alternative splicing of glucocorticoid receptor pre-mRNA to glucocorticoid receptor beta in neutrophils. PMID: 12738786
  10. Results suggest that bombesin-induced expression of SRp30c affects gllucorticoid receptor (GR) pre-mRNA splicing, leading to increased GR beta expression and contributing to glucocorticoid resistance in PC cells. PMID: 17540466
  11. Study shows that PTB can function as an anti-repressor molecule to counteract the splicing inhibitory activity of SRp30c. PMID: 17548433
  12. SRp30c stimulates splicing to the downstream 5' splice site of Bcl-x(L), thereby attenuating the repressive effect of upstream U1 snRNP binding sit PMID: 18534987
  13. findings indicate the importance of arginine methylation for the subnuclear localization of SFRS9. PMID: 19557313

Show More

Hide All

Subcellular Location
Nucleus. Note=Cellular stresses such as heat shock may induce localization to discrete nuclear bodies termed SAM68 nuclear bodies (SNBs), HAP bodies, or stress bodies. Numerous splicing factors including SRSF1/SFRS1/SF2, SRSF7/SFRS7, SAFB and KHDRBS1/SAM68 accumulate at these structures, which may participate in the post-transcriptional regulation of mRNAs in stressed cells.
Protein Families
Splicing factor SR family
Tissue Specificity
Expressed at high levels in the heart, kidney, pancreas and placenta, and at lower levels in the brain, liver, lung and skeletal muscle.
Database Links

HGNC: 10791

OMIM: 601943

KEGG: hsa:8683

STRING: 9606.ENSP00000229390

UniGene: Hs.706889

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*